Kousuke Kanemoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kousuke Kanemoto has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Yukari Tadokoro
Department of Neuropsychiatry Aichi Medical University Nagakute Japan
4 shared publications- Andres Miguel Kanner
University of Miami, Miller School of Medicine, USA
3 shared publications Tomohiro Oshima
Department of Neuropsychiatry Aichi Medical University Nagakute Japan
3 shared publications- Dong Zhou
Department of Neurology West China Hospital, Sichuan University Chengdu China
2 shared publications Hiroko Goji
Aichi Medical University, Neuropsychiatric Department, Yazako-Karimata 1-1, Nagakute, Japan
2 shared publicationsMike Kerr
Learning Disability Psychiatry Cardiff University Cardiff United Kingdom
2 shared publications
Latest Publications
- 1 April 2018
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 57, 45-49
Depression in people with epilepsy: How much do Asian colleagues acknowledge it?
- 1 April 2018
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 57, 45-49
Depression in people with epilepsy: How much do Asian colleagues acknowledge it?
- Open Access
- 9 May 2017
- Published by Wiley in Epilepsia Open
- Vol. 2 (3) , 307-316
PNES around the world: Where we are now and how we can close the diagnosis and treatment gaps—an ILAE PNES Task Force report
Summary: An international consensus clinical practice statement issued in 2011 ranked psychogenic nonepileptic seizures (PNES) among the top three neuropsychiatric problems. An ILAE PNES Task Force was founded and initially charged with summarizing the current state of the art in terms of diagnosis and treatment, resulting in two publications. The first described different levels of diagnostic certainty. The second summarized current knowledge of management approaches. The present paper summarizes an international workshop of the ILAE PNES Task Force that focused on the current understanding and management of PNES around the world. We initially provide a knowledge update about the etiology, epidemiology, and prognosis of PNES—in adults and in special patient groups, such as children, older adults, and those with intellectual disability. We then explore clinical management pathways and obstacles to optimal care for this disorder around the world by focusing on a number of countries with different cultural backgrounds and at very different stages of social and economic development (United Kingdom, U.S.A., Zambia, Georgia, China, and Japan). Although evidence‐based methods for the diagnosis and treatment of PNES have now been described, and much is known about the biopsychosocial underpinnings of this disorder, this paper describes gaps in care (not only in less developed countries) that result in patients with PNES not having adequate access to healthcare provisions. A range of challenges requiring solutions tailored to different healthcare systems emerges. Continued attention to PNES by the ILAE and other national and international neurologic, psychiatric, and health organizations, along with ongoing international collaboration, should ensure that patients with PNES do not lose out as healthcare services evolve around the world.
- 9 May 2017
- Published by Wiley in Epilepsia Open
- Vol. 2 (3) , 307-316
Open AccessPNES around the world: Where we are now and how we can close the diagnosis and treatment gaps—an ILAE PNES Task Force report
Summary: An international consensus clinical practice statement issued in 2011 ranked psychogenic nonepileptic seizures (PNES) among the top three neuropsychiatric problems. An ILAE PNES Task Force was founded and initially charged with summarizing the current state of the art in terms of diagnosis and treatment, resulting in two publications. The first described different levels of diagnostic certainty. The second summarized current knowledge of management approaches. The present paper summarizes an international workshop of the ILAE PNES Task Force that focused on the current understanding and management of PNES around the world. We initially provide a knowledge update about the etiology, epidemiology, and prognosis of PNES—in adults and in special patient groups, such as children, older adults, and those with intellectual disability. We then explore clinical management pathways and obstacles to optimal care for this disorder around the world by focusing on a number of countries with different cultural backgrounds and at very different stages of social and economic development (United Kingdom, U.S.A., Zambia, Georgia, China, and Japan). Although evidence‐based methods for the diagnosis and treatment of PNES have now been described, and much is known about the biopsychosocial underpinnings of this disorder, this paper describes gaps in care (not only in less developed countries) that result in patients with PNES not having adequate access to healthcare provisions. A range of challenges requiring solutions tailored to different healthcare systems emerges. Continued attention to PNES by the ILAE and other national and international neurologic, psychiatric, and health organizations, along with ongoing international collaboration, should ensure that patients with PNES do not lose out as healthcare services evolve around the world.
- 1 May 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 70, 61-65
Pre- and post-surgical psychiatric assessments and intervention by major epilepsy centers in Japan — Nationwide survey
- 1 May 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 70, 61-65
Pre- and post-surgical psychiatric assessments and intervention by major epilepsy centers in Japan — Nationwide survey
- 1 October 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 51, 60-64
Delusional experience awareness gap between patients and treating doctors — Self-reported EPDS questionnaire
- 1 October 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 51, 60-64
Delusional experience awareness gap between patients and treating doctors — Self-reported EPDS questionnaire
- 1 June 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 47, 6-10
Validation of the Chinese version of the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E) in West China
- 1 June 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 47, 6-10
Validation of the Chinese version of the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E) in West China
- 13 October 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (36) , 5828-5836
Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
The prevalence of depression in patients with epilepsy (PWE) is high. To elucidate the nature of depression in PWE, a comparison was made between PWE and patients with idiopathic depression (PWID), applying 3 test batteries: Beck Depression Inventory II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D) and Buss–Perry Aggression Questionnaire (BAQ). The former 2 rating scales were developed to measure depressive symptoms, while the latter was designed to detect anger and aggressive states. As a result, the group of patients with PWE showed significantly higher BAQ scores in comparison to those with PWID. Further, the BAQ and BDI scores were closely related within a group of PWE, while BAQ and BDI scores were not correlated with each other within a group of PWID. With regard to pharmaceutical therapy, the safety of antidepressants, especially SSRIs, is well established. However, there has been only one randomized controlled trial (RCT) thus far, which failed to show a significant difference in efficacy between placebo and various antidepressants. In contrast, there are two RCTs regarding the efficacy of LTG. The clinical profile of the depressiolytic effects of LTG in PWE may be different from that of antidepressants in patients with idiopathic depression, in that BAQ is more sensitive measure than BDI or CES-D. It is now widely recognized that the failure to treat depression in PWE can result in serious consequences. However, even a fundamental question, such as whether antidepressants are as effective in this population as in PWID, remains to be answered.
- 13 October 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (36) , 5828-5836
Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
The prevalence of depression in patients with epilepsy (PWE) is high. To elucidate the nature of depression in PWE, a comparison was made between PWE and patients with idiopathic depression (PWID), applying 3 test batteries: Beck Depression Inventory II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D) and Buss–Perry Aggression Questionnaire (BAQ). The former 2 rating scales were developed to measure depressive symptoms, while the latter was designed to detect anger and aggressive states. As a result, the group of patients with PWE showed significantly higher BAQ scores in comparison to those with PWID. Further, the BAQ and BDI scores were closely related within a group of PWE, while BAQ and BDI scores were not correlated with each other within a group of PWID. With regard to pharmaceutical therapy, the safety of antidepressants, especially SSRIs, is well established. However, there has been only one randomized controlled trial (RCT) thus far, which failed to show a significant difference in efficacy between placebo and various antidepressants. In contrast, there are two RCTs regarding the efficacy of LTG. The clinical profile of the depressiolytic effects of LTG in PWE may be different from that of antidepressants in patients with idiopathic depression, in that BAQ is more sensitive measure than BDI or CES-D. It is now widely recognized that the failure to treat depression in PWE can result in serious consequences. However, even a fundamental question, such as whether antidepressants are as effective in this population as in PWID, remains to be answered.
- Open Access
- 1 August 2012
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 5 (6) , 321-334
Psychotic illness in patients with epilepsy
Apart from the rather rare ictal psychotic events, such as non-convulsive status epilepticus, modern epileptic psychoses have been categorized into three main types; chronic and acute interictal psychoses (IIPs) and postictal psychosis (PIP). Together, they comprise 95% of psychoses in patients with epilepsy (PWE). Four major questions, that is, “Is psychosis in PWE a direct consequence of epilepsy or schizophrenia induced by epilepsy?”, “Is psychosis in PWE homogeneous or heterogeneous?”, “Does psychosis in PWE have symptomatological differences from schizophrenia and related disorders?”, “Is psychosis in PWE uniquely associated with temporal lobe epilepsy (TLE)?” are tried to be answered in this review with relevant case presentations. In the final section, we propose a tentative classification of psychotic illness in PWE, with special attention to those who have undergone epilepsy surgery. Psychotic disorders in PWE are often overlooked, mistreated, and consequently lingering on needlessly. While early diagnosis is unanimously supported as a first step to avoid this delay, necessity of switching from antiepileptic drugs with supposedly adverse psychotopic effects. to others is more controversial. To elucidate the riddle of alternative psychosis, we need badly further reliable data.
- 1 August 2012
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 5 (6) , 321-334
Open AccessPsychotic illness in patients with epilepsy
Apart from the rather rare ictal psychotic events, such as non-convulsive status epilepticus, modern epileptic psychoses have been categorized into three main types; chronic and acute interictal psychoses (IIPs) and postictal psychosis (PIP). Together, they comprise 95% of psychoses in patients with epilepsy (PWE). Four major questions, that is, “Is psychosis in PWE a direct consequence of epilepsy or schizophrenia induced by epilepsy?”, “Is psychosis in PWE homogeneous or heterogeneous?”, “Does psychosis in PWE have symptomatological differences from schizophrenia and related disorders?”, “Is psychosis in PWE uniquely associated with temporal lobe epilepsy (TLE)?” are tried to be answered in this review with relevant case presentations. In the final section, we propose a tentative classification of psychotic illness in PWE, with special attention to those who have undergone epilepsy surgery. Psychotic disorders in PWE are often overlooked, mistreated, and consequently lingering on needlessly. While early diagnosis is unanimously supported as a first step to avoid this delay, necessity of switching from antiepileptic drugs with supposedly adverse psychotopic effects. to others is more controversial. To elucidate the riddle of alternative psychosis, we need badly further reliable data.
- 9 June 2011
- Published by Cambridge University Press (CUP)
The Neuropsychiatry of Epilepsy
Research into the neuropsychiatry of epilepsy has become a central focus of interest in the last five years. Comorbidity of epilepsy with behavioral problems is now recognized widely, and the neuroscientific basis for such comorbidity is an active area of investigation. With an expanded international team of authors, this fully revised new edition builds on the strengths of its predecessor, examining in detail the subtleties of behavioral changes in patients with seizure disorders and offering both a diagnostic and a management perspective. New chapters cover genetic disorders, the effects of epilepsy on social behavior as viewed through theory of mind, a discussion of the precuneus, the importance and nature of peri-ictal psychiatric symptoms, depression and the interictal dysphoric disorder, and the relationship between antiepileptic drugs and suicide. This new edition is a must for anyone involved in diagnosing or managing epilepsy.
- 9 June 2011
- Published by Cambridge University Press (CUP)
The Neuropsychiatry of Epilepsy
Research into the neuropsychiatry of epilepsy has become a central focus of interest in the last five years. Comorbidity of epilepsy with behavioral problems is now recognized widely, and the neuroscientific basis for such comorbidity is an active area of investigation. With an expanded international team of authors, this fully revised new edition builds on the strengths of its predecessor, examining in detail the subtleties of behavioral changes in patients with seizure disorders and offering both a diagnostic and a management perspective. New chapters cover genetic disorders, the effects of epilepsy on social behavior as viewed through theory of mind, a discussion of the precuneus, the importance and nature of peri-ictal psychiatric symptoms, depression and the interictal dysphoric disorder, and the relationship between antiepileptic drugs and suicide. This new edition is a must for anyone involved in diagnosing or managing epilepsy.
- Open Access
Increased Frequency of Interleukin‐1β‐511T Allele in Patients with Temporal Lobe Epilepsy, Hippocampal Sclerosis, and Prolonged Febrile Convulsion
Summary: Purpose: To confirm the high frequency of interleukin (IL)‐1β‐511T allele occurrence in patients with temporal lobe epilepsy (TLE) and hippocampal sclerosis (HS), with special attention given to the impact of prolonged febrile convulsions (PFCs) on IL‐1β genotype distribution. Methods: Patients with evidence of unilateral HS on magnetic resonance (MR) images were chosen as study subjects (TLE+HS; n = 66). Other patients with essentially normal MRI findings or only foreign tissue (TLE without HS; TLE‐HS; n = 64), and those with symptomatic localization‐related epilepsy but without TLE (SLE; n = 89) were selected as disease controls. A single base pair polymorphism at position 2511 in the promoter region of the IL‐1β gene was analyzed. Results: The distribution of IL‐1β‐511 genotypes as well as allele frequency was significantly different between TLE+HS patients and controls. In contrast, no difference was found between TLE‐HS patients and controls or between SLE patients and controls. Further, in the group of patients with TLE+HS, the frequency of the IL‐1β‐511T allele tended to increase as a function of febrile convulsions [0.531 without either PFC or simple febrile convulsion (SFC); 0.633 with SFC; 0.686 with PFC]. Although no statistically significant difference was noted between patients without PFC and the controls, a χ2 analysis of allele distribution revealed a significant difference between those with PFC and the controls. Conclusions: PFC proved to be a potent determinant of IL‐1β‐511T allele frequency; thus a discrepancy of PFC incidence should be considered an explanation of recent conflicting results regarding the association between the gene polymorphisms of IL‐1β‐511 and TLE+HS.
Open AccessIncreased Frequency of Interleukin‐1β‐511T Allele in Patients with Temporal Lobe Epilepsy, Hippocampal Sclerosis, and Prolonged Febrile Convulsion
Summary: Purpose: To confirm the high frequency of interleukin (IL)‐1β‐511T allele occurrence in patients with temporal lobe epilepsy (TLE) and hippocampal sclerosis (HS), with special attention given to the impact of prolonged febrile convulsions (PFCs) on IL‐1β genotype distribution. Methods: Patients with evidence of unilateral HS on magnetic resonance (MR) images were chosen as study subjects (TLE+HS; n = 66). Other patients with essentially normal MRI findings or only foreign tissue (TLE without HS; TLE‐HS; n = 64), and those with symptomatic localization‐related epilepsy but without TLE (SLE; n = 89) were selected as disease controls. A single base pair polymorphism at position 2511 in the promoter region of the IL‐1β gene was analyzed. Results: The distribution of IL‐1β‐511 genotypes as well as allele frequency was significantly different between TLE+HS patients and controls. In contrast, no difference was found between TLE‐HS patients and controls or between SLE patients and controls. Further, in the group of patients with TLE+HS, the frequency of the IL‐1β‐511T allele tended to increase as a function of febrile convulsions [0.531 without either PFC or simple febrile convulsion (SFC); 0.633 with SFC; 0.686 with PFC]. Although no statistically significant difference was noted between patients without PFC and the controls, a χ2 analysis of allele distribution revealed a significant difference between those with PFC and the controls. Conclusions: PFC proved to be a potent determinant of IL‐1β‐511T allele frequency; thus a discrepancy of PFC incidence should be considered an explanation of recent conflicting results regarding the association between the gene polymorphisms of IL‐1β‐511 and TLE+HS.